Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NG-350A,Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akamis Begins Phase 1b FORTRESS Trial for Rectal Cancer Therapy
Details : NG-350A is a CD40 agonist gene therapy candidate, which is currenty being evaluated for the treatment of locally advanced rectal cancer.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 03, 2025
Lead Product(s) : NG-350A,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Details : NG-350A is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 14, 2024
Details : The net proceeds will fund development activities for the clinical stage NG-350A and NG-641 programs, as well as general corporate purposes. NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of vi...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : NG-350A
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
Details : NG-350A is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : NG-350A
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NG-641
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
Details : NG-641 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 14, 2021
Lead Product(s) : NG-641
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,NG-347,NG-641
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Bluebird Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study showed that when injected intravenously into mice with established human tumor xenografts, PsiOxus’ armed T-SIGn vectors reprogrammed the tumor microenvironment to a proinflammatory state.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 14, 2021
Lead Product(s) : Undisclosed,NG-347,NG-641
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Bluebird Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NG-641,Nivolumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The first stage of this collaboration combined Bristol Myers Squibb’s Opdivo with PsiOxus’ enadenotucirev in the Phase 1 SPICE study to determine the safety and tolerability of combining these two agents, and to optimise the combination intravenous d...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 07, 2021
Lead Product(s) : NG-641,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
Details : NG-641 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 05, 2021
PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment
Details : This is the first time that a tumor-specific virus containing four different therapeutic transgenes has been administered to cancer patients.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 05, 2020
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
Details : NG-641 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 12, 2019
Reset All
